Press release from Companies
Published: 2015-04-07 11:10:21
WntResearch AB’s homepage has been down temporarily. The homepage is currently working on most browsers and operating systems and is expected to run normally at the end of today.
We apologize for any inconvenience this may have caused. For additional information please contact: Nils Brünner, CEO E-mail: firstname.lastname@example.org Telephone: + 45 2614 4708 About WntResearch WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.